Salesforce Is Still Undervalued Despite a 28% Gain Over the Past Month

Salesforce’s agentic AI push (AgentForce) is driving accelerating growth: fiscal 2027 Q1 revenue rose 13% YoY and the company guided to 10%–11% YoY revenue growth for Q2. Valuation improved materially, with P/E at 24 vs. above 40 less than a year ago, while fundamentals strengthened—remaining performance obligations were $33.6B (+14% YoY) and AgentForce crossed $1B in annual recurring revenue, with combined AgentForce/Data 360 reaching $3.4B ARR (+200% YoY). The stock is up 28% over the past month as SaaSpocalypse fears eased, and net income rose 37% YoY, supporting a more bullish outlook.

Analysis

CRM is becoming a rare large-cap SaaS name where AI looks additive to, not substitutive for, the franchise. The market is starting to price that in, but the bigger mechanism is margin durability: if agentic workflows become embedded inside customer ops, switching costs rise and discount pressure falls, which supports both renewal rates and a higher terminal multiple. The stock can still rerate because 24x earnings is below large-cap software quality despite mid-teens revenue growth visibility.

The key second-order effect is competitive: if CRM proves that AI is a monetizable layer rather than a commoditizer, the pressure shifts onto lower-moat SaaS vendors whose products are easier to replicate and price-shop. That favors incumbents with large installed bases and proprietary customer data, while making it harder for smaller workflow and sales-tech names to defend pricing. NVDA is a minor indirect winner through token consumption, but this is not yet a meaningful capex impulse for semis unless enterprise AI workloads broaden materially.

The near-term catalyst path is the August print, where the market will focus less on top-line growth and more on evidence that AI is expanding deal size, not just creating demo buzz. The contrarian risk is that current enthusiasm front-runs a lot of the narrative: if Agentforce monetization is mostly upsell rather than new logo creation, growth could normalize after the initial adoption wave and the multiple would compress again. Falsifiers are simple: revenue guide below 10%, CRPO growth decelerating, or any sign that AI activity is rising without translating into durable net retention improvement.

Key Decisions for Investors

• Long CRM into the August earnings window on pullbacks, with a 1-3 month hold; risk/reward is attractive while the stock still trades at a discounted multiple versus large-cap software, but fade the position if revenue guidance slips below 10% growth or CRPO growth stalls.
• Pair long CRM / short a high-multiple SaaS basket or IGV for 1-3 months: thesis is that CRM can re-rate on proof of AI monetization while the broader software complex remains vulnerable to AI-driven substitution and pricing pressure.
• Use CRM post-earnings volatility to express a limited-risk bullish view via call spreads rather than outright stock if the run-up continues into print; this is a better structure if the market is already crowded long and you want convexity to an upside guide raise.
• Do not chase NVDA on this headline alone; treat it as a secondary beneficiary only. Reassess semis only if enterprise AI usage metrics convert into sustained capex revisions from hyperscalers over the next 1-2 quarters.